Background and Aims: Airway wall remodelling (AWR) is one of the major features of asthma pathophysiology. AWR features include, but are not limited to, increased airway smooth muscle (ASM) mass due to ASM hypertrophy and hyperplasia, mucus hypersecretion, extracellular matrix deposition and angiogenesis. Current anti-asthma therapy have limited efficacy on AWR features. Hence, new treatment options targeting AWR features in asthma are needed. Artesunate is a semi-synthetic artemisinin derivative recommended by the World Health Organisation for malarial treatment. We previously showed that artesunate attenuates airway inflammation with accompanied reductions in ASM mass via the PI3K/Akt pathway in an ovalbumin-induced acute mouse model of inflammation. We now examine the anti-AWR properties of artesunate in a house dust mite (HDM)-induced chronic mouse model of asthma, where AWR is a prominent feature.
treated with artesunate 30 mg/kg/day (or equivalent sodium bicarbonate as vehicle control). Mouse lung lobes were harvested 24 h after the last HDM challenge for immunohistochemistry, mRNA or protein analysis.
Results: Artesunate significantly attenuated HDM-induced ASM mass, as measured by sm-α actin expression. The reduction in ASM mass was not due to artesunate-induced toxicity or reduction in inflammatory cytokine levels. Artesunate also reduced HDM-induced mucus hypersecretion. However, it had limited effect on MMP9 and VEGF expressions, markers for collagen remodelling and angiogenesis respectively. Mechanistically, pre-treatment with artesunate attenuated HDMinduced cyclin D1 and p-Akt protein abundance, suggesting an involvement of the PI3K/Akt pathway in the anti-proliferative activity of artesunate in ASM cells. Background and Aims: Currently, two major endotypes of asthma have been distinguished: T2-low and T2-high asthma. In patients with severe uncontrolled asthma, it is important to identify an endotype and stratify the treatment approach. In clinical practice, the designation of the T2-high endotype is commonly used to the presence of atopy and/or eosinophilic inflammation, identified on the basis of blood eosinophil counts (B-Eos) and fraction of exhaled nitric oxide (FeNO). However, the prevalence and clinical characteristics of T2-low and T2-high endotype of severe asthma distinguished by combining type-2 biomarkers have not been well examined.
Conclusion
Methods: This retrospective study examined clinical data of 161 patients with severe uncontrolled asthma defined by ERS/ATS guidelines. T2-high asthma was determined by the presence of atopy (RAST +) and/or FeNO > 25 ppb and/or B-Eos > 300 μL −1 , while T2-low asthma was distinguished by the absence of these characteristics.
Results:
The prevalence of patients with severe uncontrolled asthma was classified into the T2-high (n = 144, 89%) and T2-low asthma (n = 17, 11%). The majority (n = 68, 47%) of patients with T2-high severe asthma showed all of atopy, blood eosinophilia, and High FeNO. Compared to the T2-low asthma patients, T2-high patients showed a significantly lower pulmonary function; FVC of predicted (median 94.5% vs 103.2%; P < 0.05), and FEV1 of predicted (median 77.5% vs 92.7%; P < 0.005). The prevalence of chronic sinusitis was higher in the T2-high than in T2-low patients (P < 0.005). There was no significant difference in the number of exacerbations during the last 12 months and ACQ score between T2-high and T2-low patients.
Conclusion:
The majority of patients with severe uncontrolled asthma was classified into the T2-high endotype by measuring the multiple type-2 biomarkers. T2-high endotype group was associated with lower lung function. 
